Agenda
19-21 October 2026
RAI Convention Centre, Amsterdam
Amsterdam, 19 - 21 October 2026
Schedule
Create your personal agenda –check the favourite icon
Oct 1910:00
Conference pass
BioNTech’s Oncology Pipeline: Combining mRNA Cancer Immunotherapies with Next-Gen Immunomodulators and Targeted Therapies
Cancer & Therapeutic Vaccines
Ruben Rizzi, SVP Global Regulatory Affairs, Safety & Pharmacovigilance, BioNTech SE
Oct 1910:00
Conference pass
Evolution of Drone Technology and Capacity Building Strategies
Vaccine Supply & Logistics
Giovanna Riggall, Head of Heath Supply Chain, Unimed
Oct 1910:00
Conference pass
Workshop Leader’s Opening Remarks
Platform Technologies
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford
Oct 1910:15
Conference pass
A Versatile Platform Technology Enabling Development Of cVLP Vaccines Within Infectious & Non-Communicable Diseases
Platform Technologies
Wian de Jongh, CEO, adaptvac
Oct 1910:15
Conference pass
Cross-reactive cellular immunity and molecular mimicry in cancer
Cancer & Therapeutic Vaccines
Oct 1910:30
Conference pass
From Forest to Finished GMP: Securing QS-21 for TB at Scale
Vaccine Supply & Logistics
Damian Hiley, Managing Director, Vaccine Division, Desert King
Session led by: 
Oct 1910:30
Conference pass
Standardized Serology: A Critical Foundation for HPV Vaccine Development and Implementation
Cancer & Therapeutic Vaccines
Oct 1910:30
Conference pass
Vaccine development using Outer Membrane Vesicle platform technology - TBC
Platform Technologies
Session led by: 
Oct 1910:45
Conference pass
Novel OMV platform for mucosal vaccines
Platform Technologies
Session led by: 
Oct 1910:45
Conference pass
Scaling Up for Global Access: Expanding Manufacturing Capacity and Supply Chains for Essential Vaccines - TBC
Vaccine Supply & Logistics
Session led by: 
Oct 1911:00
Conference pass
Discovery of viral vector based cancer vaccine
Cancer & Therapeutic Vaccines
Session led by: 
Xiaobin He, CEO, Genevoyager
Oct 1911:00
Conference pass
From API to Patient: Building an End-to-End Vaccine Supply Chain for Global Impact - TBC
Vaccine Supply & Logistics
Session led by: 
Oct 1911:00
Conference pass
Rational Design, Formulation and Process Optimization for Next-Gen mRNA-LNP Vaccines and Therapeutics
Platform Technologies
Oct 1911:15
Conference pass
Closing the Gap: Vaccine Integrity Through the Last Mile
Vaccine Supply & Logistics
Tony Fonk, CEO, SpotSee
Oct 1911:15
Conference pass
Immunity Takes Care of Your Skin: The Vaccine Reinventing Acne Treatment
Cancer & Therapeutic Vaccines
Pascal Blanc, Senior Principal Scientist, Sanofi Pasteur
Oct 1911:15
Conference pass
Revolutionizing MVA – single dose and continuous cell-line manufacturing
Platform Technologies
Senthil Ranganathan, VP, Technical Development and CMC Operations, GeoVax Labs, Inc.
Session led by: 
Oct 1911:30
Conference pass
Enabling Safe and Effective Cancer Immunotherapy: through Alithea’s liquid biopsy and AI Platforms
Cancer & Therapeutic Vaccines
Session led by: 
Oct 1911:30
Conference pass
Pandemic response with Ebola and Hantavirus - TBC
Vaccine Supply & Logistics
Session led by: 
Marta Murreddu, Business Development Director, Cerba Research
Oct 1911:45
Conference pass
mRNA LNP Platform Technology: Broad Applications in Vaccine and Therapeutic Delivery
Platform Technologies
Oct 1912:00
Conference pass
Effect of the recombinant shingles and RSV vaccines on dementia and brain health
Cancer & Therapeutic Vaccines
Maxime Taquet, Associate Professor, University of Oxford
Oct 1912:00
Conference pass
Vaccine development using recombinant Vesicular Stomatitis Virus (VSV) as platform technology
Platform Technologies
Arianna Marini, Associate Director, Global Clinical Immunology, IAVI
Oct 1912:15
Conference pass
Panel: Building Next-Generation Vaccine Platforms: Innovation, Stability, and Scalability
Platform Technologies
Mihai Bilanin, Global Regulatory Lead, GSK
Arianna Marini, Associate Director, Global Clinical Immunology, IAVI
Moderator: Jonathan Hare, Translational Science Lead, The Francis Crick Institute
Oct 1912:15
Conference pass
Panel: Modelling Supply Chain Resilience: From Digital Twins to Global Strategy
Vaccine Supply & Logistics
- What does a true “digital twin” of a vaccine supply chain look like, beyond simple forecasting models?
- How can digital twins help predict and prevent bottlenecks across manufacturing, fill-finish, and distribution?
- What data is essential to buildan accurate, end-to-end digital replica of the vaccine supply chain?
- How can simulation outputs translate into real procurement, inventory, and allocation decisions?
- Where are the current gaps between modelling insight and operational action?
Gemma Lahuerta, Parenteral Development Director, LABORATORIO REIG JOFRE, S.A.
Niall Macaulay, Policy Officer, Health Emergency Preparedness and Response Authority
Heiko Keller, Supply Chain Manager, Center for Pandemic Vaccines and Therapeutics (ZEPAI) at Paul-Ehrlich-Institute (PEI)
Oct 1912:15
Conference pass
Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts
Cancer & Therapeutic Vaccines
Oct 1912:30
Conference pass
Fireside chat: Chronic Conditions and Off-target Effects of Vaccines
Cancer & Therapeutic Vaccines
Moderator: Robbert Van der Most, CEO, Vaxxcellence
Oct 1914:00
Conference pass
Reducing Zero-Dose Vaccinations in Africa: Digital Strategies and Continental Initiatives
Vaccine Safety & Access
Fidele Ngabo Gaga, Head of RMNCAH Division, Africa CDC
Oct 1914:00
Conference pass
Oct 1914:00
Conference pass
Workshop Leader’s Opening Remarks
Vaccine Delivery
David Burkhart, CEO, Inimmune Corp
Oct 1914:15
Conference pass
Global market landscape of vaccine manufacturing and procurement for improved access
Vaccine Safety & Access
Georgios Stathopoulos, Technical Officer, Vaccine Access, World Health Organization
Oct 1914:15
Conference pass
Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery.
Vaccine Delivery
Moderator: Joe Keenan, Director Business Development, Daicel
Session led by: 
Oct 1914:15
Conference pass
Panel: Preparing for Disease X: Approaches for the Next Spillover
Biothreats & Disease X
- How can human, animal, and environmental health systems work together to detect and reduce zoonotic spillover risks at their source?
- What lessons fromrecentspillovers (e.g.Hantavirus,Bundibugyo virus,Avian influenza) should inform future surveillance, vaccine development, and response strategies?
- How can governments, researchers, and industry strengthen cross-sector collaboration before and during the next Disease X event?
- What role should vaccines play in proactive prevention, rapid platform deployment, and stockpiling?
Nicola Lewis, Director of Worldwide Influenza Centre, The Francis Crick Institute
Ab Osterhaus, Director of Research Center For Emerging Infections and Zoonoses and Professor, University of Veterinary Medicine Hannover
Meghan Pennini, Director, Translational Science, Foundation for the National Institutes of Health
Jerome Kim, Director General, IVI
Oct 1914:30
Conference pass
Systems Biology to Define Actionable Biomarkers of Vaccine Safety
Vaccine Safety & Access
Oct 1914:45
Conference pass
Assessing and Monitoring Vaccine Safety in the AI Era
Vaccine Safety & Access
Oct 1915:00
Conference pass
Panel: Accelerating Safe Access to Vaccines: How Expedited Pathways Are Working in Practice
Vaccine Safety & Access
- Where do reliance and expedited pathways genuinely speed access without compromising safety?
- What has worked, and what has broken down, in real regulatory submissions?
- How do we move from pilots and one-off successes to predictable, trusted pathways?
Ana Milinkovic, Global Regulatory Lead, GSK
Nicholas Perombelon, Head of Vaccines and Therapies, EMA
Ruben Rizzi, SVP Global Regulatory Affairs, Safety & Pharmacovigilance, BioNTech SE
Dakshina Reddy, Head of Global Regulatory Strategy and Operations, Bill & Melinda Gates Medical Research Institute
Oct 1915:30
Conference pass
Pandemic flu: mRNA H5 vaccine
Biothreats & Disease X
Anthony Pajot, Global Project Head, Sanofi Vaccines
Oct 1915:45
Conference pass
Digitally Enabled Vaccine Delivery in Wales
Vaccine Delivery
Wales built its national vaccination platform one campaign at a time. The Welsh Immunisation System began as a pandemic response and grew, increment by increment, into the system that now delivers the winter respiratory programmes (COVID-19, RSV and flu) across all seven health boards, with more than 13 million vaccinations recorded.
This talk follows what that platform makes possible once it sits on common data standards and a shared record from stock to surveillance. Because every dose is recorded once, in structured and FHIR-compliant form, and shared through the system. The same data supports high-quality effectiveness and safety studies. WIS data contributed to the four-nation UK study of RSV vaccine effectiveness published in The Lancet Regional Health (Europe) in 2026, which found adjusted effectiveness against hospitalisation of 82% in Wales. The same record also lifts uptake: it identifies who is eligible, prioritises by clinical risk, prompts invitations and reminders, and shows where coverage is falling short by deprivation in near real time.
Wales is now extending the platform to school-age immunisation, beginning with MenB in late summer 2026, on the way to delivering every vaccine, end to end, within one digital solution. The session is for anyone working at the implementation end of the value chain, and it sets out where the opportunities lie for manufacturers, funders and researchers who need delivery and real-world evidence at national scale.
Oct 1915:45
Conference pass
Gavi, the Vaccine Alliance: Driving Global Vaccine Access and Market Shaping
Vaccine Safety & Access
Maria Verykiou, Policy Manager, Gavi, the Vaccine Alliance
Oct 1916:00
Conference pass
Combination Vaccines Pre-Congress Workshop Chair
Combination Vaccines
Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization
Oct 1916:00
Conference pass
Inside the New Advisory Landscape for Public Health Emergencies in Europe
Biothreats & Disease X
Oct 1916:00
Conference pass
Novel combination vaccines against endemic pathogens for children under 5 years old.
Combination Vaccines
Farzana Muhib, Asia Team Lead, Vaccine Implementation, PATH
Oct 1916:15
Conference pass
Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence
Biothreats & Disease X
Ankur Mutreja, Director of External Affairs and Health Security, South Asia-PATH
Oct 1916:15
Conference pass
Panel: Vaccine Acceptance: Safety, Communication and Access
Vaccine Safety & Access
- How do we communicate rare adverse events with context and proportionality?
- When recommendations change, how do we explain why without damaging confidence?
- What are the distinct roles ofregulators, government, manufacturersand clinicians invaccinecommunication?
- What are the main system-level barriers to vaccine uptake?
Elissa R Weitzman, Associate Professor, Director of Research, Boston Children's Hospital, and Harvard Medical School
Sibilia Quilici, Executive Director, Vaccines Europe
Oct 1916:30
Conference pass
Novel approaches to measure the value of combination vaccines
Combination Vaccines
Create your personal agenda –check the favourite icon
Oct 209:00
Conference pass
The Technology Revolution: Agility for the Wave of Next Generation Vaccines
Keynotes
- What new vaccines are on the horizon and what are our key scientific leaders championing?
- How close are we to precision immunology?What is the roadmap for platform vaccines in oncology, autoimmune disorders, and infectious diseases?
- What are the key performance and logistical benefits of advanced platforms(e.g. RNA)compared to traditional vaccine approaches?
- Which platformtechnologies are most likely to cut response timelines and deliver on the 100-day mission?
- How are regulatory agencies adapting their approval pathways to novel vaccines, new antigens andusing AI in vaccine R&Dandmanufacturing?
Marco Cavaleri, Head of Public Health Threats, European Medicines Agency
Jerome Kim, Director General, IVI
Jean-Francois Toussaint, Global Head of Research and Development Vaccines, Sanofi
Lucy Chappell, Chief Scientific Adviser, UK Department of Health and Social Care
Track 1
Oct 2010:15
Conference pass
One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime
Keynotes
- How can combination vaccines support life-course immunisation strategies and close immunity gaps at every age?
- Could combining priority pathogens in a single shot improve vaccine coverage, or will it introduce new barriers for uptake and delivery?
- What isthe economic value of combination vaccines?
- What standards do we need to ensure multi-antigen vaccines perform consistently without compromising safety or effectiveness?
- What strategies can we use to ensure broad accessibility of combination vaccines, including considerations around technology, adjuvants, and formulation?
- Which pairings have the strongest potential to reduce global disease burden, especially in regions with limited resources?
Nicola Rose, Interim Executive Director of Science and Research, MHRA
Rituparna Das, Therapeutic Area Head, Respiratory Vaccines, Moderna
Mark Jit, Chair and Professor, Department of Global and Environmental Health, NEW YORK UNIVERSITY
Track 1
Oct 2014:00
Conference pass
Architects of immunity: Future vaccines using state-of-the-art adjuvant - TBC
Formulation & Bioprocess
Session led by: 
Track 2
Oct 2014:00
Conference pass
Clinical Trials Track Chair
Clinical Trials
Track 3
Oct 2014:00
Conference pass
H5N1 Preparedness: A CRO’s Strategic Response to Emerging Threats - TBC
COVID & Beyond
Session led by: 
Track 5
Oct 2014:00
Conference pass
HIV vaccine design in nonhuman primates
Pre-Clinical Development
Richard Wyatt, Director Viral Immunology, IAVI Center for Neutralizing Antibodies, The Scripps Research Institute
Track 6
Oct 2014:00
Conference pass
Learnings from CD4 T-cell immune profiling: how the past determines the future
Immune Profiling
Robbert Van der Most, CEO, Vaxxcellence
Track 4
Oct 2014:00
Conference pass
Pragmatic Randomised Vaccine Trials: Generating the Evidence Policymakers Need
Clinical Trials
Track 3
Oct 2014:00
Conference pass
Revolutionizing Vaccine Downstream Processing with Advanced Membrane Filtration Technologies - TBC
Technology Showcases
Session led by: 
Track 1
Oct 2014:15
Conference pass
Beyond Binding: Broad Fc Effector Function Profiling to Accelerate Vaccine and Immunotherapy Development
Immune Profiling
Lenny Moise, VP, Research, SeromYx
Session led by: 
Track 4
Oct 2014:15
Conference pass
Needle-Free, Cold Chain–Independent Vaccines via Electro-hydrodynamic Processing - TBC
Formulation & Bioprocess
Session led by: 
Track 2
Oct 2014:30
Conference pass
Accelerating Vaccine Quality Control with Next-Generation Sequencing
Technology Showcases
Session led by: 
Antoine Millet, Viral Safety and Regulatory Affairs Specialist, PathoQuest
Track 1
Oct 2014:30
Conference pass
Delivering Clinical Trials in Africa
Clinical Trials
Session led by: 
Adriana Bastidas, Head of Medical Strategy & Safety, P95 BV
Track 3
Oct 2014:30
Conference pass
LNP-mediated delivery for mRNA vaccines: from infectious diseases to multi-antigen cancer immunotherapy
COVID & Beyond
Session led by: 
Edward Grahame, BioPharma Services Alliance Manager, Cytiva
Track 5
Oct 2014:30
Conference pass
Research and development of vaccines against Enterovirus D68
Pre-Clinical Development
Session led by: 
Track 6
Oct 2014:30
Conference pass
The Recombinant Advantage: Enhancing Virus Titer and Stability Without the Serum-Derived Risks
Formulation & Bioprocess
Session led by: 
Track 2
Oct 2014:45
Conference pass
Accelerating vaccine immune profiling with multiplexing solutions for serum and single-cell analysis
Immune Profiling
Tyler Sandberg, Product Manager, Assays, Mabtech
Session led by: 
Track 4
Oct 2014:45
Conference pass
High-Throughput Analytics for Streamlining Formulation and Bioprocess Stability Testing - TBC
Formulation & Bioprocess
Session led by: 
Track 2
Oct 2014:45
Conference pass
Serological assays: a tool for vaccine evaluation and pandemic preparedness - TBC
Clinical Trials
Track 3
Oct 2016:00
Conference pass
A circular RNA vaccine to treat infectious and other diseases - TBC
Technology Showcases
Session led by: 
Track 1
Oct 2016:00
Conference pass
Beyond COVID-19 and strategies for better mRNA vaccines
COVID & Beyond
Session led by: 
Track 5
Oct 2016:00
Conference pass
Clinical Trials Track Chair
Clinical Trials
Track 3
Oct 2016:00
Conference pass
Multiplexing neutralisation for priority pathogens
Immune Profiling
Track 4
Oct 2016:00
Conference pass
Novel Expression Systems to Accelerate Yield and Stability in Pre-Clinical Vaccine Candidates - TBC
Pre-Clinical Development
Session led by: 
Track 6
Oct 2016:00
Conference pass
Panel: Expanding the Access & Impact of Adjuvants
Formulation & Bioprocess
- How can we overcome IPand licensing challenges to make novel adjuvants more globally accessible?
- How can regulators harmonize approval pathways for adjuvanted vaccines without compromising safety or slowing innovation?
- How can collaboration between academia, industry, and funders, accelerate development and equitable distribution of new adjuvants?
- What emerging adjuvant platforms or innovative technologies are available that could transform next-generation vaccines, and what obstacles exist to their deployment?
Session led by:
Daniel Fullen, Research and Development Innovations Lead, CEPI
Track 2
Oct 2016:15
Conference pass
Eliminating the Cold Chain: A Fridge-Free Td Vaccine From Concept to Clinical Trials - TBC
Clinical Trials
Session led by: 
Karen O'Hanlon, Chief Development Officer, Stablepharma
Track 3
Oct 2016:15
Conference pass
Persistent Neurobiological Consequences of SARS-CoV-2 Infection: Multimodal Evidence from Non-Human Primate Models
COVID & Beyond
Session led by: 
Track 5
Oct 2016:15
Conference pass
Platform for Manufacturing Broad-Protecting Protein-Based Vaccines Against Fast-Evolving Viruses
Technology Showcases
Paco Pino, VP R&D, ExcellGene
Session led by: 
Track 1
Oct 2016:15
Conference pass
Using AI to design multivalent vaccine candidates against multiple filoviruses
Pre-Clinical Development
Clara Schoeder, Assistant Professor, University of Leipzig
Track 6
Oct 2016:30
Conference pass
Advancing COVID-19 vaccination strategies: integrating science, technology and real-world insights
COVID & Beyond
Session led by: 
Track 5
Oct 2016:30
Conference pass
Enabling tomorrow's RNA therapies - from lab to patients at scale
Technology Showcases
Session led by: 
Blerina Shkodra, Chief Scientific Officer, leon-nanodrugs GmbH
Track 1
Oct 2016:30
Conference pass
Gamma PN a serotype -independent pneumococcal vaccine – early clinical and immunogenicity data - TBC
Clinical Trials
Session led by: 
Track 3
Oct 2016:30
Conference pass
LungVax - vaccine targeting of neoantigens to prevent lung cancer
Immune Profiling
Mariam Jamal-Hanjani, Professor of Cancer Genomics and Metastasis Research Department of Oncology, UCL Cancer Institute - Paul OGorman Building
Track 4
Oct 2016:30
Conference pass
Preclinical development of a West Nile virus RNA vaccine
Pre-Clinical Development
Track 6
Oct 2017:10
Conference pass
One Health in Action: Connecting Human, Animal, and Environmental Health to Advance Vaccine Strategy
Keynotes
- How can integratedOne Healthsurveillanceguide vaccine prioritisation across humans, animals, and ecosystems?
- What joint funding models and pipeline management strategiescan acceleratehigh-risk zoonotic diseaseslike avian influenza?
- How can insights from spillover events, vector ecology, and AMR shape vaccine strategy andpandemicpreparedness?
- What cross-sector partnerships are most effective in translatingOne Healthprinciples into coordinated vaccine actionand policy?
Moderator: Keith Sumption, Former Chief Veterinary Officer, FAO
Robb Butler, Director, Division of Communicable Diseases Environment and Health, World Health Organisation (WHO)
Erick Lelouche, President, LYONBIOPOLE
Thomas Waite, Deputy Chief Medical Officer, UK Department of Health
Javier Yugueros-Marcos, Head of Antibiotic Resistance and Veterinary Products, World Organisation for Animal Health
Track 1
Create your personal agenda –check the favourite icon
Oct 219:00
Conference pass
The New Geopolitics of Vaccines: Global Vaccine Manufacturing in a Fractured World
Keynotes
- How can public-private partnerships mitigate the risks of vaccine nationalism?
- How toensureequitableaccess to vaccines andmaintainingmanufacturing continuity across global hubs during a public health emergency?
- What innovative manufacturingtechnologies(modularmanufacturing,digital twins,etc.)canspeed upresponsesandpandemicpreparedness?
- Howcould governments and industry balance the push for domestic manufacturing sovereignty with the efficiencies and interdependencies of a globalised supply network?
Petro Terblanche, Chief Executive Officer, Afrigen Biologics (Pty) Ltd
Jean Kaseya, Director General Africa CDC, The Africa Centres of Disease Control and Prevention (Africa CDC)
Wolfgang Philipp, Principal Adviser for Health and Crisis Management, Directorate-General for Health and Food Safety (SANTE), European Comission
Leila Gharagozloo Pakkala, Director of Supply Division, UNICEF SD
Track 1
Oct 2110:30
Conference pass
Bioprocess & Manufacturing Track Chair: Richard Welch
Bioprocess & Manufacturing
Richard Welch, VP BioProcess Develpment and Manufacturing, IAVI
Track 2
Oct 2110:30
Conference pass
Chair’s opening remarks
One Health & Veterinary
Jeremy Salt, Chief Executive Officer, The Vaccine Group
Track 4
Oct 2110:30
Conference pass
Chair’s opening remarks
Respiratory
Jerald Sadoff, Chief Medical Officer, Centivax
Track 5
Oct 2110:30
Conference pass
FinDementia - A Pragmatic phase 4 trial designed to demonstrate effectiveness of recombinant shingles vaccine against dementia
Clinical Trials
Arto A. Palmu, Chief Scientific Officer, FVR – Finnish Vaccine Research | FVR – Suomen rokotetutkimus
Track 3
Oct 2110:30
Conference pass
How can a microneedle manufacturer contribute to the success of cancer vaccine developers?
Biopharma Showcases
Jeffrey Stolwijk, Scientific Director, Uneedle
EXPO
Oct 2110:30
Conference pass
Results from the Phase 3 E.mbrace study: Exploring the Lack of Efficacy of a 9-Valent Vaccine (ExPEC9V) for the Prevention of Invasive Escherichia coli Disease in Older Adults
AMR & Bacterial Vaccines
Track 6
Oct 2110:30
Conference pass
Vaccine candidate targeting the Bundibugyo strain of Ebola
Emerging & Infectious Diseases
Track 1
Oct 2110:45
Conference pass
Avian Flu (H5N1): Status of Livestock Vaccination Policies in the EU and Global Trade Implication
One Health & Veterinary
Sanna Mesman, Policy Officer, European Comission
Track 4
Oct 2110:45
Conference pass
Innovative Adjuvants for Global Health
Bioprocess & Manufacturing
Peter Tygesen, Business Development Director, SPI Pharma
Session led by: 
Track 2
Oct 2110:45
Conference pass
Novel influenza vaccine combining adjuvant and cell tech (aTIVc)
Respiratory
Raja (S) Rajaram, Head of Global Medical Strategy, Seqirus
Track 5
Oct 2110:45
Conference pass
Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response
Emerging & Infectious Diseases
- How do we spot outbreaks earlier in practice, not just in theory? What role do surveillance, genomics, community reporting, and data sharing really play on the ground?the critical role of medical interventions, particularly vaccines, in managing andcontainingemergingand infectious disease outbreaks.
- What role do medical countermeasures, particularly vaccines, play in recent outbreak responses (e.g.hantavirus, Bundibugyo virus, avian influenza), and how are these experiences shaping preparedness around speed, coordination, and decision-making under uncertainty?
- Where are the biggest gaps right now, funding, manufacturing readiness, regulatory pathways, or last-mile delivery, and who needs to act first?
Marcus Lacey, Exec Director Global Pandemic, CSL Seqirus
Folake Olayinka, Director of Immunisation, Africa CDC
Track 1
Oct 2110:45
Conference pass
Streamline your RSV early development program from FIH to POC CHIM
Clinical Trials
Session led by: 
Jelle Klein, Medical Director CPU, SGS Belgium NV.
Track 3
Oct 2111:00
Conference pass
Accelerating Vaccine Development: End to End Manufacturing and Innovation Platform - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2111:00
Conference pass
AI-Immunology™-Powered Development of a Staphylococcus aureus Vaccine - TBC
AMR & Bacterial Vaccines
Session led by: 
Track 6
Oct 2111:00
Conference pass
Expanding the Toolkit for HPV Research: A Versatile Platform for HPV Vaccine Immunological Studies - TBC
Clinical Trials
Session led by:
Track 3
Oct 2111:00
Conference pass
FluSNIFF-Toddler: Driving Innovation and Access in Primary Care Research
Biopharma Showcases
Oct 2111:00
Conference pass
Panel: Rethinking Livestock Vaccination for Emerging Threats
One Health & Veterinary
- How will investments in pandemic-prevention vaccines affect the development of vaccines for emerging zoonotic threats in livestock?
- How do regulatory systems for human and animal vaccines differ, and is it realistic to achieve similar approval speeds for both?
- How can we balance rapid vaccine deployment with food safety, ecological, and trade risks, and do the benefits of live attenuated vaccines(e.g. for ASF)outweigh potential biosafety concerns?
- How can economic incentives, such as advanced market commitments, best accelerate the development and market entry of new livestock vaccines?
Volker Gerdts, Director and Chief Executive Officer, VIDO
Javier Yugueros-Marcos, Head of Antibiotic Resistance and Veterinary Products, World Organisation for Animal Health
Track 4
Oct 2111:30
Conference pass
Antigen optimization for infectious disease vaccines using AI-Immunology™ - TBC
Emerging & Infectious Diseases
Session led by:
Track 1
Oct 2111:30
Conference pass
Efficacy, immunogenicity, and safety of intranasal quadrivalent inactivated whole influenza virus vaccine in healthy Japanese aged 13–64 years: Results of Phase II and Phase III studies
Clinical Trials
Session led by:
Track 3
Oct 2111:30
Conference pass
High infection rates achieved with the worlds’ first RSV B challenge model; a key component of our RSV-hMPV-PIV combination vaccine efficacy testing platform – TBC
Respiratory
Session led by: 
Track 5
Oct 2111:30
Conference pass
Redefining Nanocarrier Manufacturing with Scalable Continuous scCO₂ Processing for Advanced Vaccine Delivery
Biopharma Showcases
Elissandro KLEIN, R&D Manager, Biotech One
Session led by: 
Oct 2111:30
Conference pass
The development and manufacturing of Human Viral Challenge Agents (HVCA), a safe GMP solution for accelerating vaccine development - tbc
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2112:00
Conference pass
Building Advocacy Groups and Communicating Vaccines in Public Health in an Era of Misinformation and Mistrust
Working Groups
Kashmira Date, Medical, pfizer
Oct 2112:00
Conference pass
The way forward: how do we ensure that the priority combination vaccines are developed, licensed and used?
Working Groups
Farzana Muhib, Asia Team Lead, Vaccine Implementation, PATH
Marco Cavaleri, Head of Public Health Threats, European Medicines Agency
Oct 2112:15
Conference pass
Reducing Risk and Enabling Scalable Viral Vaccine Manufacturing Through Serum-Free Media
Bioprocess & Manufacturing
Session led by: 
Madhavsai Gajjar, Upstream Processing (USP) Field Application Scientist., Thermo Fisher
Oct 2112:15
Conference pass
VXV-01, a vaccine targeting Candida and healthcare-associated priority Gram-negative bacterial infections
AMR & Bacterial Vaccines
Session led by: 
Track 6
Oct 2113:00
Conference pass
Global Manufacturing and Access Strategy for a TB Vaccine: MTBVAC
AMR & Bacterial Vaccines
Track 6
Oct 2113:10
Conference pass
French Biomanufacturing : a dynamic network
International Bioclusters
Paul-Henri Derrien, Industrial Director, France Biolead
EXPO
Oct 2113:15
Conference pass
Avian influenza viruses: how to cope with antigenic diversity for pandemic preparedness and vaccine design?
Respiratory
Rory De Vries, Associate Professor, Erasmus M.C.
Track 5
Oct 2113:15
Conference pass
Efficacy of Early Vaccination Against Avian Influenza in Commercial Poultry
One Health & Veterinary
Kim Bouwman, Wageningen University
Track 4
Oct 2113:15
Conference pass
Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance using Real-World Data from Prospective Observational Studies: a PrIMAVeRa-Ecraid partnership
AMR & Bacterial Vaccines
Elske Sieswerda, Clinical Microbiologist and Epidemiologist, Ecraid
Valentjin Schweitzer, Clinical Microbiologist and Epidemiologist, University of Utrecht
Track 6
Oct 2113:15
Conference pass
Unlocking the potential of inline process analytical technology (PAT) for advanced bioprocess development, scale-up, and control
Bioprocess & Manufacturing
Katharina Dahlmann, Application and PAT Expert, HAMILTON BONADUZ AG
Session led by: 
Track 2
Oct 2113:30
Conference pass
Advancing European Competitiveness: Innovation in Vaccine Manufacturing Technology through AI, ML, and Modeling
Bioprocess & Manufacturing
Track 2
Oct 2113:30
Conference pass
Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D
Clinical Trials
Faith Osier, Co-director, Imperial College London
Christine Dahlke, Translational Immunology Lead, CEPI
Track 3
Oct 2113:30
Conference pass
Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle
AMR & Bacterial Vaccines
- How to define bacterial priorities for AMR vaccine and monoclonal antibody R&D (pathogen, region, health economics).
- Role of modelling and cost-effectiveness frameworks
- Aligning funders, PDPs, and pharma around the biggest-impact targets
Irina Meln, Head of Innovation, European Vaccine Initiative
Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization
Nina van Sorge, Head of Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam UMC
Mark Geels, Senior Director, IAVI
Ankur Mutreja, Director of External Affairs and Health Security, South Asia-PATH
Track 6
Oct 2113:40
Conference pass
Belgium as a Vaccine Clinical Trials Hub: Fast, Reliable Clinical Trials in a Strong Regulatory Ecosystem
International Bioclusters
- The National Competent Authorities as part of the European Medicines Regulatory Network
- National initiatives to attract vaccine clinical trials in Belgium
- Performance of Belgium for vaccine trials since the application of the Clinical Trial Regulation
Nele Steens, Head of R&D Division, FAGG
EXPO
Oct 2113:45
Conference pass
A novel strategy for a vaccine development and commercialization engine
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 2113:45
Conference pass
Using AI to advance respiratory diagnosis and in estimating disease burden - TBC
Respiratory
Kashmira Date, Medical, pfizer
Track 5
Oct 2114:00
Conference pass
From mucosal immunology to nasal vaccines: a scientific journey
Respiratory
Session led by: 
Track 5
Oct 2114:00
Conference pass
The Potential of Novavax’s Technology Platform, including Matrix-M® adjuvant
Emerging & Infectious Diseases
Track 1
Oct 2114:10
Conference pass
From Emergency Response to Permanent Preparedness: Italy's Investment in Strategic Health Infrastructure and the European Vaccine Hub
International Bioclusters
Gianluca Polifrone, General Manager, Fondazione Biotecnopolo di Siena
EXPO
Oct 2114:15
Conference pass
From Kit to Custom: Development of an Accurate In-House Host Cell DNA and Sizing Assay - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2114:15
Conference pass
Neutralising antibody is a poor predictor of protection by candidate EBV vaccines
Emerging & Infectious Diseases
Alexander Douglas, Associate Professor, University of Oxford
Track 1
Oct 2114:15
Conference pass
New Tuberculosis Vaccines
Respiratory
Track 5
Oct 2114:15
Conference pass
Next-Generation Vaccines: Integrating VLP and VLP-cRNA Platforms for Broad-Spectrum, Durable Protection - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2114:15
Conference pass
Novel CHIMs for Influenza, RSV, and C. difficile: Results from INNO4VAC
Clinical Trials
Track 3
Oct 2114:30
Conference pass
Optimizing Downstream Processing for Next-Generation Vaccine Development - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2114:30
Conference pass
Panel: Bridging Species: Veterinary Vaccine Innovation for a Shared Health Future
One Health & Veterinary
- How can platform technologies such as mRNA and viral vectors be adapted and approved efficiently across species?
- How can modern vaccine platforms (e.g., mRNA, viral vectors) be adapted and scaled for livestock and wildlife, and approved efficiently across species? How can human vaccine sites be used to manufacture animal vaccines?
- How do we incentivise R&D for high-impact livestock and wildlife diseases with limited commercial return?
- What models ensure equitableaccess to veterinary vaccines, particularly in LMICs?
- How can veterinary vaccination reduce antimicrobial use and support AMR strategies?
Moderator: Keith Sumption, Former Chief Veterinary Officer, FAO
Catrina Stirling, Director, Regulatory Affairs, Zoetis
Ab Osterhaus, Director of Research Center For Emerging Infections and Zoonoses and Professor, University of Veterinary Medicine Hannover
Track 4
Oct 2114:30
Conference pass
Panel: Why Is TB Still Stuck? Applying Respiratory Vaccine Innovation to the Top Infectious Killer
Respiratory
- How must clinical trial design evolve to support the next generation of respiratory vaccines, and what lessons from RSV, COVID and influenza can be applied to TB to shorten timelines without compromising rigor?
- How cannewbiomarkersand digitaldiagnostics helpusidentifyhigh-risk patientsearlier and improve trial efficiency for TB and other respiratory pathogens?
- TB is often treated as a "neglected" disease. How do we shift the narrative to make TB a corerespiratoryvaccinepriority for global health security and private-sector investment?
Morten Ruhwald, Chief Medical Officer, Novo Nordisk Foundation Initiative for Vaccines and Immunity
Ole Olesen, Professor, European Vaccine Initiative
Judith Kallenberg, Global Health Access Programs and Partnerships Lead, GSK
Puck Pelzer, Associate director, IAVI
Track 5
Oct 2114:30
Conference pass
Priority disease lists for new vaccines to reduce antimicrobial use
One Health & Veterinary
Track 4
Oct 2114:30
Conference pass
Update on Lyme Disease Vaccine
AMR & Bacterial Vaccines
Track 6
Oct 2114:45
Conference pass
Applying Modelling Informed Drug Development (MIDD) to Vaccine Design and Specification Setting
Clinical Trials
Rajat Desikan, Director, GSK
Track 3
Oct 2114:45
Conference pass
From Meningococcus to Gonococcus: A Vaccine Journey Across Two Pathogens
AMR & Bacterial Vaccines
Mariagrazia Pizza, Chair in Microbiology, Imperial College London
Track 6
Oct 2114:45
Conference pass
Update on Hookworm Vaccine Initiative
Emerging & Infectious Diseases
Track 1
Oct 2115:00
Conference pass
Continuous xRNA Manufacturing and Advanced LNP Encapsulation: Streamlining the Path from Sequence to Drug Product - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2115:00
Conference pass
Estimating the burden of chikungunya in East Africa to inform vaccine evaluation and deployment
Emerging & Infectious Diseases
George Warimwe, Professor of Vaccinology, University of Oxford
Track 1
Oct 2115:00
Conference pass
Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling
Clinical Trials
- How can modelling bridge the interface between CMC parameters, clinical data, and trial design to better support development and regulatory decision-making?
- What evidence do regulators need to gain confidence in modelling-driven approaches, including adaptive trials and model-informed regulatory submissions?
- Can modelling meaningfully reduce trial size, timelines, or dose arms while stillmaintainingconfidence in safety and efficacy outcomes?
- How valuable are model-informed approaches during accelerated development or emergency situations, and are we overestimating what models can reliably predict from limited early-stage data?
Moderator: Andrew Deavin, Senior Director, GSK
Mats Welin, Senior Expert, Medical Products Agency Lakemedelsverket
Francois Beckers, Sanofi
Track 3
Oct 2115:00
Conference pass
The world is waiting for a Klebsiella vaccine, where are we?
AMR & Bacterial Vaccines
Track 6
Oct 2115:15
Conference pass
Malaria vaccines
Emerging & Infectious Diseases
Track 1
Oct 2115:15
Conference pass
Oct 2115:15
Conference pass
Neonatal sepsis
AMR & Bacterial Vaccines
Track 6
Oct 2115:15
Conference pass
Title TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2115:30
Conference pass
From DNA to Dose: Automated Cell-Free Systems for Decentralised Vaccine Production
Bioprocess & Manufacturing
Jonathan Jones, Manager - Microbial Fermentation, Cpi
Track 2
Oct 2115:30
Conference pass
Priority disease lists for new vaccines to reduce antimicrobial use
One Health & Veterinary
Track 4
Oct 2115:30
Conference pass
TBC
Respiratory
Kashmira Date, Medical, pfizer
Track 5
Oct 2115:30
Conference pass
Update on Pneumococcal vaccines
AMR & Bacterial Vaccines
David Goldblatt, Professor of Vaccinology and Immunology and Director of Clinical Research and Development, ucl
Track 6
Oct 2116:00
Conference pass
Europe’s Vision for Global Health Security: Designing Sustainable Vaccine Financing and Preparedness Systems
Keynotes
- How can Europedefineevidence-based criteriato decidewhen eradication, elimination,or long-term control of major infectious threats(i.e.Health Threat Prioritisation Assessment formedicalcountermeasures)is achievable and desirable?
- What economic models and tools are needed to ensure predictable, long-term investment in vaccine R&D, manufacturing platforms, and preparedness infrastructureand implementation of immunisation programs?
- How can European institutions pivot global R&D and preparedness financing from reactive, crisis-driven surges to mission-oriented, multi-decade planning?
- Which policy levers, such as long-term contracts, advance market commitments, and pooled procurement, can reliably diversify andstabilize vaccine supply for both routine immunisation and emergency response?
Maarten Postma, Chair, Faculty of Economics & Business,, University of Groningen
Charlie Weller, Head of Vaccines, Wellcome Trust
Thomas Waite, Deputy Chief Medical Officer, UK Department of Health
Track 1
last published: 25/Jun/26 13:25 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events